Anti-B9D1/ B9/ EPPB9 functional antibody
Anti-B9D1/ B9/ EPPB9 functional antibody for cell culture, ELISA & in-vivo assay
Go to B9D1/B9D1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE1455-Ab-1/ GM-Tg-hg-SE1455-Ab-2 | Anti-Human B9D1 monoclonal antibody | Human |
GM-Tg-rg-SE1455-Ab-1/ GM-Tg-rg-SE1455-Ab-2 | Anti-Rat B9D1 monoclonal antibody | Rat |
GM-Tg-mg-SE1455-Ab-1/ GM-Tg-mg-SE1455-Ab-2 | Anti-Mouse B9D1 monoclonal antibody | Mouse |
GM-Tg-cynog-SE1455-Ab-1/ GM-Tg-cynog-SE1455-Ab-2 | Anti-Cynomolgus/ Rhesus macaque B9D1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE1455-Ab-1/ GM-Tg-felg-SE1455-Ab-2 | Anti-Feline B9D1 monoclonal antibody | Feline |
GM-Tg-cang-SE1455-Ab-1/ GM-Tg-cang-SE1455-Ab-2 | Anti-Canine B9D1 monoclonal antibody | Canine |
GM-Tg-bovg-SE1455-Ab-1/ GM-Tg-bovg-SE1455-Ab-2 | Anti-Bovine B9D1 monoclonal antibody | Bovine |
GM-Tg-equg-SE1455-Ab-1/ GM-Tg-equg-SE1455-Ab-2 | Anti-Equine B9D1 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE1455-Ab-1/ GM-Tg-hg-SE1455-Ab-2; GM-Tg-rg-SE1455-Ab-1/ GM-Tg-rg-SE1455-Ab-2; GM-Tg-mg-SE1455-Ab-1/ GM-Tg-mg-SE1455-Ab-2; GM-Tg-cynog-SE1455-Ab-1/ GM-Tg-cynog-SE1455-Ab-2; GM-Tg-felg-SE1455-Ab-1/ GM-Tg-felg-SE1455-Ab-2; GM-Tg-cang-SE1455-Ab-1/ GM-Tg-cang-SE1455-Ab-2; GM-Tg-bovg-SE1455-Ab-1/ GM-Tg-bovg-SE1455-Ab-2; GM-Tg-equg-SE1455-Ab-1/ GM-Tg-equg-SE1455-Ab-2 |
Products Name | Anti-B9D1 monoclonal antibody |
Format | mab |
Target Name | B9D1 |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-B9D1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE1455-Ag-1 | Recombinant multi-species B9D1/ B9/ EPPB9 protein |
Target information
Target ID | GM-SE1455 |
Target Name | B9D1 |
Gene ID | 27077,27078,287383,702949,479519,101097602,505335,100063389 |
Gene Symbol and Synonyms | B9,B9D1,EPPB9,JBTS27,MKS9,MKSR-1,MKSR1 |
Uniprot Accession | Q9UPM9,P0C5J2 |
Uniprot Entry Name | B9D1_HUMAN,B9D1_RAT |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000108641 |
Target Classification | N/A |
The target: B9D1, gene name: B9D1, also named as B9, EPPB9, JBTS27, MKS9, MKSR1. This gene encodes a B9 domain-containing protein, one of several that are involved in ciliogenesis. Alterations in expression of this gene have been found in a family with Meckel syndrome. Meckel syndrome has been associated with at least six different genes. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Mar 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.